Table 1.
Characteristics | Young adultsa (N = 20,629) | Middle-aged adults (N = 16,889) | Older adults (N = 4,322) |
---|---|---|---|
Type (%) | |||
Methylphenidate | 18,381 (89.10%) | 14,672 (86.87%) | 3,584 (82.92%) |
Atomoxetine | 3,236 (15.69%) | 2,232 (13.22%) | 547 (12.66%) |
Lisdexamfetamine | 137 (0.66%) | 177 (1.05%) | 33 (0.76%) |
Amfetamine | 141 (0.68%) | 337 (2.00%) | 218 (5.04%) |
Dexamfetamine | 442 (2.14%) | 945 (5.60%) | 254 (5.88%) |
Guanfacine | 7 (0.03%) | 1 (0.01%) | 1 (0.02%) |
Source (%) | |||
Primary care | 280 (1.36%) | 145 (0.86%) | 69 (1.60%) |
Specialist careb | 1,393 (6.75%) | 1,065 (6.31%) | 454 (10.50%) |
Psychiatric care | 18,956 (91.89%) | 15,679 (92.84%) | 3,799 (87.90%) |
Duration of medication (%) | |||
Single prescriptionc | 1,438 (6.97%) | 686 (4.06%) | 197 (4.56%) |
Short term (≤6 months) | 2,189 (10.61%) | 1,164 (6.89%) | 273 (6.32%) |
Medium term (6–12 months) | 2,434 (11.80%) | 1,424 (8.43%) | 310 (7.17%) |
Long term (>12 months) | 14,568 (70.62%) | 13,615 (80.61%) | 3,542 (81.95%) |
Young adults refer to patients aged 18–29 years; middle-aged adults refer to patients aged 30–49 years; older adults referred to patients aged 50–64 years.
Specialist care excluding psychiatry.
Single prescription here entails single dispensed prescriptions of any ADHD medication. Switching between different types of ADHD medications is not captured by this number.